• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

April 23, 2018
Company Drug/Device Medical Condition Status
Pfizer, Inc. PF-06939926 Duchenne muscular dystrophy (DMD) Phase Ib trial initiated
Synlogic SYNB1618 Phenylketonuria (PKU) Phase I/IIa trial initiated
NovoCure Ltd. STELLAR mesothelioma Phase II top-line results announced evaluating 80 subjects
Fervent Pharmaceuticals FP-101 vasomotor symptoms Phase IIa trials initiated enrolling 112 subjects from across the southeastern U.S.
Janssen Pharmaceutical Companies of Johnson & Johnson esketamine major depressive disorder at imminent risk for suicide Phase IIa results announced evaluating 68 subjects
Glenmark Pharmaceuticals GBR 830 moderate-to-severe atopic dermatitis Phase IIb trials initiated enrolling 392 subjects
Amgen Aimovig (erenumab) migraine Phase IIIb final results announced evaluating 246 subjects
Genentech, Inc. HEMLIBRA (emicizumab-kxwh) hemophilia A without factor VIII Breakthrough Therapy Designation granted by the FDA
King-Devick technologies, inc. K-D Balance conditions that could affect balance 510(k) clearance granted by the FDA
Alkermes ALKS 54641 major depressive disorder NDA filed with the FDA
NeuroVive Pharmaceutical AB KL1333 inherited mitochondrial respiratory chain diseases (MRCD) Orphan Drug Designation granted by the FDA
Boehringer Ingelheim Pharmaceuticals, Inc. Praxbind (idarucizumab) patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding FDA approved

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing